Risperidone ER (Risperdal Consta®)

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, founded in 2002 and publicly traded (NYSE: AMRX), has evolved from a generic drug company into a diversified biopharmaceutical enterprise with a mission to make medicine accessible for all. Its strategy is built on a three-pillar portfolio of complex generics, biosimilars, and specialty injectables, supported by significant U.S. manufacturing reinvestment. Recent high-profile launches like Brekiya for migraine and CREXONT for Parkinson's disease demonstrate its capability to develop and commercialize advanced, difficult-to-formulate products that address unmet patient needs and generate sustainable growth.

Therapeutic Areas